SUPN · XBRL financial data

Supernus Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (SUPN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	154	144	168	176	174*	150	165	192	212*	208	219	227
Cost of goods and services sold	20	16	18	18	26*	16	17	19	23*	23	34	27
Research and development	23	25	26	29	29*	27	22	29	28*	39	29	26
Selling, general and administrative	83	87	86	70	79*	90	94	180	122*	125	134	128
Operating income (loss)	8	(3)	23	41	21*	(10)	12	(60)	(4)*	(8)	(58)	21
Interest expense	0	0	0	0	0*	—	0	0	0*	—	2	1
Other income (expense)	2	3	4	4	5*	4	5	2	2*	2	—	—
Income tax expense (benefit)	26	0	6	6	11*	6	(6)	(13)	2*	(4)	1	2
Net income (loss)	(16)	0	20	38	15*	(12)	22	(45)	(4)*	(2)	(58)	21
Earnings per share, basic USD per share	(0.29)	0.00	0.36	0.70	0.28*	(0.21)	0.40	(0.80)	(0.07)*	(0.04)	(1.01)	0.36
Earnings per share, diluted USD per share	(0.29)	0.00	0.36	0.69	0.27*	(0.21)	0.40	(0.80)	(0.07)*	(0.04)	(1.01)	0.35
Weighted average shares, basic millions of shares	55	55	55	55	55*	56	56	57	57*	58	58	58
Weighted average shares, diluted millions of shares	55	56	56	56	56*	56	57	57	57*	58	58	59

Fiscal quarters (SUPN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	95	63	52	32	69	116	145	151	128	185	180	176
Accounts receivable	142	148	152	145	142	146	141	171	188	182	212	215
Inventory	83	75	68	64	54	49	44	107	112	111	107	113
Prepaid and other current assets	24	24	23	27	36	29	31	62	65	78	56	50
Total current assets	449	544	591	640	686	688	739	594	644	732	723	711
Property and equipment, net	14	13	12	12	12	11	11	11	11	10	10	10
Right-of-use asset	29	30	28	26	24	23	22	29	27	26	25	23
Goodwill	117	117	117	117	117	117	117	119	125	121	119	119
Total assets	1,285	1,304	1,316	1,343	1,368	1,347	1,382	1,420	1,453	1,501	1,428	1,398
Accounts payable	3	14	5	6	5	7	8	8	3	10	6	9
Accrued liabilities	78	86	83	76	76	77	78	109	108	101	108	109
Total current liabilities	288	315	309	292	292	282	286	331	338	374	347	285
Lease liability, non-current	34	33	30	29	27	26	24	31	30	30	29	29
Total liabilities	373	375	358	336	332	317	319	370	391	424	397	335
Retained earnings	481	483	503	541	556	545	567	522	518	516	457	478
Total stockholders' equity	912	929	957	1,007	1,036	1,031	1,064	1,050	1,062	1,077	1,031	1,062
Total liabilities and equity	1,285	1,304	1,316	1,343	1,368	1,347	1,382	1,420	1,453	1,501	1,428	1,398
Common shares outstanding (cover page) millions of shares	55	55	55	55	56	56	56	57	58	58	58	58

Fiscal quarters (SUPN's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(16)	0	20	38	15*	(12)	22	(45)	(4)*	(2)	(58)	21
Stock-based compensation	8*	6	7*	8*	8*	8	8*	8*	10*	8	9*	9*
Depreciation and amortization	22*	21	21*	20*	19*	20	21*	25*	25*	26	26*	24*
Net cash from operating activities	36*	38	36*	54*	44*	31	59*	(62)*	20*	67	(5)*	7*
Purchases of property and equipment	0*	0	0*	0*	0*	0	0*	0*	0*	0	1*	0*
Net cash from investing activities	35*	(52)	(49)*	(77)*	(13)*	37	(31)*	49*	(51)*	(19)	7*	8*
Proceeds from issuing common stock	(0)*	3	2*	3*	7*	2	3*	24*	9*	14	4*	2*
Net cash from financing activities	(0)*	2	2*	3*	6*	(21)	1*	21*	9*	9	(7)*	(18)*
Net change in cash	70*	(12)	(11)*	(20)*	38*	47	29*	8*	(23)*	56	(5)*	(4)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Supernus Pharmaceuticals	176	227	6.6*	58.2M	—	Q3 FY26 10-QSep 30, 2026
Sarepta Therapeutics	571	401	197*	105.6M	—	Q2 FY26 10-QJun 30, 2026
Amicus Therapeutics	214	185*	16*	314.0M	—	Q4 FY25 10-KDec 31, 2025
Ocular Therapeutix	599	13	(67)*	219.6M	8.9 quarters	Q2 FY26 10-QJun 30, 2026
Ligand Pharmaceuticals	56	79	(28)*	20.0M	—	Q3 FY26 10-QSep 30, 2026
Apellis Pharmaceuticals	405	268	(61)	128.0M	6.6 quarters	Q1 FY26 10-QMar 31, 2026
Indivior Pharmaceuticals	305	356	97*	118.0M	—	Q3 FY26 10-QSep 30, 2026
Biocryst Pharmaceuticals	155	not reported	104*	255.5M	—	Q2 FY26 10-QJun 30, 2026
Agios Pharmaceuticals	100	45	(57)*	59.7M	10.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.